Inventor
XU WEIMING
CN25 patents
⚠️ This page may combine multiple inventors who share the name “XU WEIMING”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV HANGZHOU NORMAL
7 patentsUS10604466B1Mar 31, 2020
Method for preparing resveratrol compound
UNIV HANGZHOU NORMAL2 citations69
US11414415B2Aug 16, 2022
6H-imidazo[4,5,1-ij]quinolone, synthesis method and use thereof
UNIV HANGZHOU NORMAL0 citations61
US11161818B2Nov 2, 2021
Quinolone derivatives, preparation methods and application thereof
UNIV HANGZHOU NORMAL0 citations60
US11577228B2Feb 14, 2023
Porous layered transition metal dichalcogenide and preparation method and use thereof
UNIV HANGZHOU NORMAL0 citations56
US11161809B2Nov 2, 2021
Processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac
UNIV HANGZHOU NORMAL0 citations52
US10125119B2Nov 13, 2018
Series of resveratrol-derivative fluorescently labeled molecules and synthesis method thereof
UNIV HANGZHOU NORMAL0 citations45
US10611721B2Apr 7, 2020
Method for preparing levobunolol hydrochloride
UNIV HANGZHOU NORMAL0 citations43
VMWARE INC
5 patentsUS11736441B2Aug 22, 2023
Management of blacklists and duplicate addresses in software defined networks
VMWARE INC0 citations59
US11533294B2Dec 20, 2022
Management of blacklists and duplicate addresses in software defined networks
VMWARE INC0 citations59
US11258757B2Feb 22, 2022
Management of blacklists and duplicate addresses in software defined networks
VMWARE INC0 citations59
US11689499B2Jun 27, 2023
Management of endpoint address discovery in a software defined networking environment
VMWARE INC0 citations58
US11115379B2Sep 7, 2021
Management of endpoint address discovery in a software defined networking environment
VMWARE INC0 citations58
SIGNAL PHARM LLC
4 patentsUS9155736B2Oct 13, 2015
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SIGNAL PHARM LLC16 citations82
US10004735B2Jun 26, 2018
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
SIGNAL PHARM LLC4 citations71
US9737535B2Aug 22, 2017
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
SIGNAL PHARM LLC5 citations71
US9557338B2Jan 31, 2017
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity
SIGNAL PHARM LLC1 citations50
PERRIN-NINKOVIC SOPHIE
3 patentsUS8492381B2Jul 23, 2013
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PERRIN-NINKOVIC SOPHIE44 citations95
US8110578B2Feb 7, 2012
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PERRIN-NINKOVIC SOPHIE67 citations95
US8507492B2Aug 13, 2013
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway
PERRIN-NINKOVIC SOPHIE22 citations90
HANGZHOU TRANSFAR FINE CHEMICAL CO LTD
2 patentsUS12240938B2Mar 4, 2025
2,2-dimethyl-1,3-dioxolan-4-yl-methyl 2-bromo-2,2-difluoroacetate, waterborne polyurethane, and preparation methods thereof
HANGZHOU TRANSFAR FINE CHEMICAL CO LTD0 citations48
US11242307B1Feb 8, 2022
Method for preparing alkynyl 2-halo-2,2-difluoroacetate
HANGZHOU TRANSFAR FINE CHEMICAL CO LTD0 citations41